Cell therapy for inherited retinal disease (CLARICO)
Part of Brain & nervous system, Ear, nose & throat, Eyes & vision, Genetic & congenital clinical trials.
This study tests a new cell therapy (OpCT-001) for adults with inherited retinal diseases that affect the light-sensing cells. It aims to see if the treatment is safe and possibly helps improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis of a primary photoreceptor disease (a type of inherited eye condition that affects the light-sensing cells in your retina).
- Your vision in the study eye must fall within a specific range: for Phase 1, between counting fingers and 20/40; for Phase 2, between 20/25 and 20/60 on an eye chart.
- Your retina must have areas that are suitable for the study treatment to be injected.
- You cannot have active eye inflammation, infection, glaucoma, diabetic eye disease, or significant macular edema.
- You cannot have had any prior cell therapy, gene therapy, retinal implant, or organ transplant.
- You must not have had eye surgery in the last 3 months or have a current or recent (within 5 years) cancer (except treated basal cell skin cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy injection (UGX202) for people with advanced retinitis pigmentosa (RP) who have very poor vision. It aims to see if the treatment can help improve or preserve sight.
This trial tests a new gene therapy injection (ZM-02) that uses light-sensitive proteins to help restore vision in people with advanced retinitis pigmentosa. It’s designed to see if the treatment is safe and can improve vision.
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
This early-phase trial studies a gene therapy medicine called TTX-381 to see if it is safe and tolerable in people with CLN2 disease that affects the eyes. The study also looks at how well the treatment fits into existing eye enzyme therapy care.
This trial tests an experimental gene therapy (OPGx-RDH12-1001) injected under the retina to treat a rare form of inherited vision loss called LCA caused by RDH12 gene mutations. It aims to see if the treatment is safe and tolerable for people with advanced vision loss.
Hear when a new Usher Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.